Merck's Idvynso offers the first integrase-free HIV switch option, Replimune cuts 60% of staff after a second FDA rejection, and Kailera's $625M debut signals where obesity investment is headed next.
The Largest Biotech IPO on Record and a New…
Merck's Idvynso offers the first integrase-free HIV switch option, Replimune cuts 60% of staff after a second FDA rejection, and Kailera's $625M debut signals where obesity investment is headed next.